Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3033)	10/19/2014 2:27:24 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

Updated...... Tuck has found another clinical-stage project from Rhizen. GILD - Idelalisib INCY - INCB40093 and INCB050465 TGTX - TGR-1202 (Rhizen license) INFI - IPI-145 and IPI-443 (delta/gamma, IPI-145 licensed to AbbVie, $275M upfront, INFI retains rights to IPI-443) Rhizen - RP6530 (delta/gamma) More? Pharma projects that will make me look silly when we see their advanced status?? :-) Also of potential interest, there will be a Treg and PI3Kdelta presentation at SITC. eventscribe.com (under "barriers to successful vaccines", Saturday 8 November)